Aucheer Pre-eclampsia test kit iRaTe

Product catalog summary

Preeclampsia Overview
Preeclampsia is a severe hypertensive disorder in pregnancy, typically developing after 20 weeks and potentially leading to multiorgan dysfunction. It poses a significant threat to maternal safety globally, contributing to preterm births, maternal morbidity, and stillbirths.

Key Biomarkers: PlGF and sFlt-1
Placental Growth Factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are critical biomarkers for predicting preeclampsia. In women who later develop preeclampsia, PlGF levels decline significantly as early as 11 weeks of gestation, while sFlt-1 levels rise markedly after 22 weeks.

Screening and Prediction
The best method for predicting preeclampsia involves a combined test of maternal risk factors, Mean Arterial Pressure (MAP), PlGF, and Uterine Artery Pulsatility Index (UTPI). First-trimester screening is optimal, with PlGF being the most effective biochemical marker. The sFlt-1/PlGF ratio is used to predict the short-term absence of preeclampsia.

Guidelines and Recommendations
All pregnant women should be evaluated for preeclampsia at various gestational stages. The PARROT study supports PlGF testing as a diagnostic adjunct, while the PROGNOSIS study suggests using an sFlt-1/PlGF ratio of 38 or lower for prediction.

Prevention Strategies
Low-dose aspirin (150 mg/day) is effective in preventing preeclampsia in high-risk populations, with a prevention efficacy of 62%-82%. However, aspirin intake below 100 mg/day does not significantly reduce preeclampsia incidence.

High-Risk Factors
Factors increasing preeclampsia risk include advanced maternal age, first pregnancy, obesity, multiple pregnancies, and certain comorbidities. The FMF Triple Test enhances detection rates by combining maternal risk factors with MAP and PlGF.

Clinical Utility of Repeat PlGF Measurements
Repeat PlGF measurements are useful in stratifying women with suspected preeclampsia, demonstrating high negative predictive value for determining the need for delivery within 14 days.

Conclusion
Effective management of preeclampsia involves early prediction, regular monitoring, and preventive measures such as aspirin administration. The integration of PlGF and sFlt-1 testing into clinical practice can significantly improve outcomes for pregnant women at risk of preeclampsia.

Catalog excerpts

SCREENING, PREVENTION AND PREDICTION OF PREECLAMPSIA PlGF, sFlt-1 安孕希号 TM G Hypeesrttational ension Prematurye Deliver PlGF\ sFlt-1 NINGBO AUCHEER BIOTECHNOLOGY CO.

Open the catalog to page 1

？ Preeclampsia & PlGF,sFlt-1 Preeclampsia: A Severe Threat to Global Maternal Safety Preeclampsia is a sort of severe hypertensive disorders in pregnancy which usually develops after 20 weeks, and can process into a multiorgan dysfunction of varying clinical features. Global hypertensive disorders of pregnancy cases annually, with 40% presenting severe symptoms Globally, preeclampsia-driven preterm births account for 15% of all preterm births Global maternal deaths caused by preeclampsia. Global cases of severe maternal morbidity linked to preeclampsia Global stillbirths associated with preeclampsia...

Open the catalog to page 2

Maternal Risk Factors + MAP + PIGF |± I_I_L UTPI Processing comprehensive risk evaluation including maternal risk factors, MAP, PIGF & UTPI at 11-13+6 weeks [2] High risk £1/100 Routine prenatal examination Aspirin for prevention121 I Women with suspeted preeclampsia risk negative predictive risk positive predictive Routine prenatal examination Dynamic detection risk negative predictive high risk positive value 99.3% predictive value 36.75 Routine prenatal examination Dynamic detection | PIGF<12pg/ml, high ; imminent PE/adverse outcomes risk Hospital monitoring sFlt-l/PIGF>85pg/ml, high imminent...

Open the catalog to page 3

Prediction & Prevention of Preeclampsia in First Trimester High Risk Factors of Preeclampsia in First Trimester Assisted Reproduction Afro-Caribbean or South Asian Comorbidities (Hyperglycemia in pregnancy, hypertension, Chronic nephrosis, Autoimmune disease) Advanced maternal age (≥35 years old) First pregnancy Nulliparity Obesity（BMI≥30 Kg/m2） Multiple Pregnancy （Interpregnancy Interval <12 months or >72 months) Previous history/family history of preeclampsia The FMF Triple Test Increased The Detection Rate of Preeclampsia 41% FMF Triple Test Maternal Risk Factors + MAP + PlGF ± UTPI (DR) Traditional...

Open the catalog to page 4

Second & Third Trimester Preeclampsia Risk Screening SUSPECTED SYMPTOMS OF PREECLAMPSIA IN SECOND AND THIRD TRIMESTER Suspected symptoms of preeclampsia (meet any one or more of the options 1-5)： 1 2 3 4 5 New-onset of hypertension Worsening of existing hypertension New-onset of proteinuria Worsening of existing proteinuria Other suspected clinical causes o f preeclampsia (as shown in a-j) a.Epigastric or right upper-quadrant pain b.Excessive edema (face, hands, feet) c.A headache with visual disturbances d.Uncontrollable weight gain e.Liver transaminase elevation f.(Su spected) intrauterine...

Open the catalog to page 5

0 Aucheer™ “One-Stop” SolutionFluorescence Immunoassay System Full-automatic Chemiluminescence Detection System Instrument CV<3%, Reagent CV<15% PIGF:10~5000pg/mL Serurru Plasma Model Principle Sample Volume Through-put Time to First Result Accuracy Detection Range Sample Material Operation Mode Applicability Acridine ester direct chemiluminescence On Arrival Test,Batch Test,Emergency Test Outpatient & Paramedical Department Clinical laboratory, central laboratory, prenatal diagnosis center Full Pregnancy Cycle Health Management Protocol Adolescence PreconcePt'on Pregnancy Sex Hormone(AMH FSH...

Open the catalog to page 6

All AUCHEER BIOTECHNOLOGY catalogs and technical brochures

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.

Brand list